Cancer Mutational Signatures Professors and Supervisors | ApplySharif

جست‌وجوی استاد و پژوهشگر

استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشی‌تان را پیدا کنید و با او ارتباط بگیرید.

نمایش ۱۶-۳۰ از ۶۵۹ استاد راهنما

اطلاعات این پروفایل‌ها از صفحات عمومی دانشگاه‌ها جمع‌آوری شده و ممکن است به‌روز نباشد.

Jonathan Hugginsمشاهده پروفایل

استادیار

Boston UniversityUnited States

Jonathan Huggins is an Assistant Professor at Boston University, affiliated with the Department of Mathematics & Statistics and the Faculty of Computing & Data Sciences. He holds a Ph.D. in Computer Science from MIT (2018) and a B.A. in Mathematics from Columbia University (2012). His research focuses on developing fast, trustworthy machine learning and Bayesian methods that balance computational efficiency and statistical optimality, with applications in ecological forecasting and genomic data analysis. Education: Ph.D. in Computer Science, Massachusetts Institute of Technology (2018) B.A. in Mathematics, Columbia University (2012) Research Interests: Large-scale machine learning and Bayesian computation Robust statistical inference Applications in genomics and ecological modeling Algorithmic development for scalable inference Key Projects: Stochastic Methods for Data Science: A book on stochastic processes and algorithms VIABEL: A Python package for variational inference and diagnostics ShorTeX: A LaTeX package for mathematical writing Recent Articles: Focus on scalable Bayesian methods, error bounds for iterative algorithms, and mutational signature discovery. His work emphasizes reproducibility and robustness in statistical inference. Awards: Blackwell–Rosenbluth Award (Outstanding Junior Bayesian Researcher) Grants & Funding: Supported by NIH, NSF, and the Department of Defense. Active in advising students across multiple BU programs. Labs/Teams: Affiliated with the BU URBAN Program, Program in Bioinformatics, and Department of Computer Science.

پروفایل رسمی دانشگاه

Andrew Godwinمشاهده پروفایل

استاد

University of KansasUnited States

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

پروفایل رسمی دانشگاه

Nigel Leeمشاهده پروفایل

مدرس

University of QueenslandAustralia

Dr. Nigel Lee is a Lecturer and NHMRC Emerging Leadership Fellow at the University of Queensland's School of Nursing, Midwifery and Social Work. He also serves as an Adjunct Associate Professor with the Molly Wardaguga Research Centre at Charles Darwin University and is affiliated with the Centre for Innovation in Pain and Health Research (CIPHeR). Dr. Lee completed his PhD in 2013 at Australian Catholic University, researching sterile water injections for managing back pain in labour. His research interests span midwifery care, labour pain management, breastfeeding support, perineal trauma prevention, and consent practices during childbirth. He has developed significant expertise in randomized controlled trials and mixed methods research design, with a strong focus on translating research into clinical practice. His recent publications (2023-2025) demonstrate continued productivity across multiple areas of maternal health, with particular emphasis on labour induction trends, breastfeeding education, perineal trauma prevention, and consent practices during labour and birth. These works reflect his commitment to improving evidence-based midwifery practice through rigorous research. Scientific Awards: NHMRC Emerging Leadership Fellow NHMRC Investigator Grant (2023-2027) for 'Water injections: Transforming childbirth pain management for any woman, anywhere' Dr. Lee actively supervises multiple PhD and Master's students across various topics including respectful maternity care, perineal trauma prevention, and breastfeeding support. His current NHMRC-funded projects extend through 2027, demonstrating sustained research productivity. He collaborates extensively with researchers across Australia, Sweden, the UK, and the USA, reflecting his strong international research network. Dr. Lee's work bridges clinical practice and research, with a clear focus on improving maternal health outcomes through evidence-based practice. His leadership in the Consortium for Sterile Water Injections Research and Training (ConSIRT) demonstrates his commitment to translating research findings into practical clinical applications.

پروفایل رسمی دانشگاه

G. Petur Nielsenمشاهده پروفایل

استاد

RWTH Aachen UniversityGermany

G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms

پروفایل رسمی دانشگاه

Natalia Buzaمشاهده پروفایل

استاد

Yale UniversityUnited States

Dr. Natalia Buza is a Professor of Pathology at Yale School of Medicine with a distinguished career specializing in gynecologic and breast pathology. She serves as Director of Women's Health Pathology and Director of both the Gynecologic Pathology and Women's Health Pathology Fellowship Programs at Yale. Dr. Buza earned her medical degree from the University of Pecs Med and Health Science Center in Hungary, followed by residency and fellowship training at Yale University, where she joined the faculty in 2010. Professor of Pathology, Yale School of Medicine Director, Pathology Center of Excellence for Women's Health, Anatomic Pathology Director, Gynecologic Pathology Fellowship Program Director, Women's Health Pathology Fellowship Program Secretary, International Society of Gynecological Pathologists (ISGyP) Dr. Buza's research focuses on gestational trophoblastic disease, ovarian neoplasms, and uterine cancers, with particular expertise in morphological and microscopic analysis of gynecological pathologies. Her work bridges diagnostic pathology with clinical applications, contributing significantly to precision medicine approaches in gynecologic oncology. She has authored over 160 publications, including review articles, book chapters, and a textbook on Intraoperative Frozen Section in Gynecologic Pathology. Her recent publications demonstrate a strong focus on molecular characterization of endometrial and ovarian cancers, HER2 testing methodologies, gestational trophoblastic disease diagnostics, and targeted therapies for gynecologic malignancies. Dr. Buza's work frequently incorporates advanced molecular techniques like STR genotyping and next-generation sequencing to improve diagnostic precision and treatment selection. The Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents (2016) Dr. Buza serves as Section Editor for Archives of Pathology and Laboratory Medicine and Pathology and Oncology Research, and sits on the editorial boards of Modern Pathology, International Journal of Gynecological Pathology, and Human Pathology. She is a domain expert for the International Collaboration on Cancer Reporting datasets on Gestational Trophoblastic Tumors and Endometrial Cancer, and frequently serves as course faculty for major pathology organizations including ASCP and USCAP.

پروفایل رسمی دانشگاه

Peng Maoمشاهده پروفایل

دانشیار

Stony Brook UniversityUnited States

Peng Mao is an Associate Professor in the Department of Pathology at the Renaissance School of Medicine, Stony Brook University . His research focuses on DNA damage repair mechanisms in chromatin, transcriptional regulation of repair pathways, and cancer cell adaptation to chemotherapeutic agents. Education: BS: Huazhong University of Science and Technology, China PhD: Peking University, China Postdoc: Washington State University, Pullman, WA The Mao Research Lab employs next-generation sequencing (NGS) and bioinformatics to investigate: (1) DNA repair protein dynamics in chromatin; (2) Transcription machinery's impact on DNA repair pathways; (3) Cancer-driven modulation of repair mechanisms to evade chemotherapy. His work bridges genomic instability and cancer therapy resistance . His recent publications highlight studies on UV-induced mutagenesis , cisplatin resistance , transcription-coupled repair , and chromatin remodeling complexes . These articles span genomic mapping , histone modifications , and transcription factor interactions in DNA repair contexts. Labs & Teams: Mao Research Lab, Stony Brook University

پروفایل رسمی دانشگاه

Abhijit Patelمشاهده پروفایل

دانشیار

Yale UniversityUnited States

Abhijit Patel, MD, PhD is an Associate Professor of Therapeutic Radiology at Yale School of Medicine and serves as the Medical Director of the Lawrence & Memorial Cancer Care Center in Waterford. His work focuses on developing innovative liquid biopsy approaches for cancer detection and monitoring, with particular emphasis on circulating tumor DNA analysis. Dr. Patel received his medical education at Yale University School of Medicine (MD, 2003) and completed his PhD in Molecular Biophysics and Biochemistry from Yale University Graduate School (2002). His training includes an internship at Memorial Sloan-Kettering Cancer Center (2004), residency in Radiation Oncology at Harvard Medical School (2008), and postdoctoral research at the Howard Hughes Medical Institute, Massachusetts General Hospital (2008). His research program centers on developing ultrasensitive diagnostic tools to measure trace amounts of circulating tumor DNA molecules through analysis of genomic and epigenomic signatures. Dr. Patel's work addresses key challenges in liquid biopsy technology, including assay development for circulating tumor DNA detection, high-throughput RNA profiling, and clinical applications for early cancer detection, treatment response assessment, and monitoring treatment resistance. His research draws upon expertise from clinical oncology, molecular biology, chemistry, computer science, and microfluidics. Analysis of Dr. Patel's recent publications reveals a strong focus on advancing liquid biopsy technologies for cancer detection and monitoring. His work spans technical innovations in DNA sequencing and analysis, clinical validation studies across multiple cancer types (particularly lung cancer), and collaborative efforts through the Liquid Biopsy Consortium to address challenges in early cancer detection. His research consistently aims to bridge the gap between molecular diagnostics and clinical oncology practice. Lungevity Foundation Early Detection Award (2015) Tina's Wish Foundation Research Award (2015) ASTRO Junior Faculty Career Research Training Award (2011) Brozman Foundation Fellowship (2011) American Cancer Society Institutional Research Grant (2010) Dr. Patel serves as a sub-investigator on multiple clinical trials focused on cancer detection and treatment, including studies on adjuvant radiotherapy for head and neck cancer, mechanisms of treatment resistance in lung cancer, and peripheral blood profiling for lung cancer screening. He leads the Patel Lab at Yale, which collaborates extensively with scientists and clinicians across disciplines to advance liquid biopsy technologies for clinical implementation.

پروفایل رسمی دانشگاه

Cristian Tomasettiمشاهده پروفایل

استاد

Beckman Research Institute of City of HopeUnited States

Cristian Tomasetti serves as Professor and Director of the Early Detection and Prevention Division at City of Hope's Beckman Research Institute, where he leads the Division of Mathematics for Cancer Evolution and Early Detection within the Department of Computational and Quantitative Medicine. His work bridges mathematical modeling with cancer biology to develop novel approaches for cancer detection and prevention. Dr. Tomasetti's research focuses on the mathematical foundations of cancer etiology, evolution, and early detection. His laboratory has pioneered algorithms for early cancer detection using cell-free DNA sequencing and protein data, developing some of the first multi-analyte blood tests capable of identifying cancer at its earliest stages. His work on cancer evolution has produced the most comprehensive mathematical models of tumorigenesis currently available, providing critical insights into mutation rates, driver gene requirements, and fitness advantages in cancer development. His influential research on the relationship between stem cell divisions and cancer risk has reshaped understanding of cancer etiology. The analysis of Dr. Tomasetti's recent publications reveals a consistent focus on liquid biopsy technologies, particularly circulating tumor DNA analysis for early cancer detection and monitoring. His work spans multiple cancer types including colorectal, pancreatic, ovarian, and bladder cancers, with a strong emphasis on translating mathematical models into clinically applicable diagnostic tools. The research demonstrates an evolution from theoretical models of cancer development to practical applications in cancer screening, risk assessment, and treatment monitoring. Dr. Tomasetti has established himself as a leader in the field of mathematical oncology, with his laboratory at the forefront of developing computational approaches to cancer prevention and early detection. His work on cell-free DNA testing has significant potential to transform cancer screening paradigms, moving toward less invasive and more effective methods for detecting cancer before symptoms appear.

پروفایل رسمی دانشگاه

Emanuel Petricoinمشاهده پروفایل

استاد

George Mason UniversityUnited States

Emanuel Petricoin is a Professor and Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University's School of Systems Biology, a position held since 2005 with prior leadership at the FDA-NCI Clinical Proteomics Program (1993-2005). His academic affiliation spans proteomics, molecular medicine, and precision oncology within GMU's research ecosystem. His educational background includes: Ph.D. in Microbiology from the University of Maryland, College Park (1990) Dr. Petricoin pioneers clinical proteomics for personalized therapy and biomarker discovery, with seminal work in cancer signaling pathways, tumor microenvironment analysis, and diagnostic assay development. His research integrates proteogenomics, phosphoproteomics, and functional protein analysis to address therapeutic resistance in breast and pancreatic cancers. As a translational scientist, he bridges laboratory innovation with clinical implementation through FDA-regulated platforms. Analysis of his 2024-2025 publications reveals dominant themes in proteogenomic tumor characterization, KRAS/HER2 pathway dynamics, and biomarker-guided immunotherapy. Key trends include spatial proteomics of tumor heterogeneity, extracellular vesicle-mediated signaling, and quantitative assessment of drug targets for precision oncology decision-making. The work consistently emphasizes clinical applicability through CLIA-certified assays and molecular tumor boards. His scientific recognition includes: University Professorship at George Mason University NIH Director’s Award FDA Distinguished Scientist Award 2015 Innovator of the Year Award GAP50 Top Virginia Entrepreneurs Nifty 50 Award American Society of Cytopathology Basic Research Award Roche Diagnostics/CLAS Distinguished Scientist Award Harvard University Leading Edge Award Dr. Petricoin drives research commercialization as co-founder of four biotech firms (Theranostics Health, Ceres Nanosciences, C-4 Diagnostics, Perthera) and co-inventor of 40+ patents. His editorial leadership spans Proteomics, Cancer Epidemiology Biomarkers and Prevention, and other high-impact journals. He actively shapes national initiatives as a HUPO founding member and Virginia Health Research Biosciences Corporation board representative. The CAPMM under his co-direction serves as a national hub for clinical proteomics, specializing in reverse-phase protein array (RPPA) technology, laser capture microdissection, and biomarker validation for direct patient care applications. The center integrates multi-omic data to advance personalized cancer therapy through industry partnerships and clinical trial support.

پروفایل رسمی دانشگاه

Sheng Liمشاهده پروفایل

دانشیار

University of Southern CaliforniaUnited States

Sheng Li is an Associate Professor of Cancer Biology at the University of Southern California's Keck School of Medicine. She co-leads the Epigenetic Regulation in Cancer Program at the Norris Comprehensive Cancer Center. Her research integrates multi-omics and computational approaches to study epigenetic heterogeneity in blood cancers, aging, and clonal hematopoiesis. Her lab focuses on single-cell spatial multi-omics, 3D epigenomics, and long-read sequencing to map epigenetic drivers of leukemogenesis. Awards include the Leukemia & Lymphoma Society Scholar Award and AACR NextGen Star recognition. She mentors PhD students and postdocs, with her team publishing extensively in high-impact journals. Her publications demonstrate a strong emphasis on computational epigenetics, cancer systems biology, and geroscience. Recent work includes developing tools for spatial transcriptomics interpretation and modeling IDH-mutant AML gene networks.

پروفایل رسمی دانشگاه

Fabio Lucianiمشاهده پروفایل

استاد

University of New South WalesAustralia

Fabio Luciani is a Professor in Systems Immunology and Machine Learning at the School of Medical Sciences at UNSW Sydney, with visiting fellow positions at the Garvan Institute for Medical Research and Weill Cornell College of Medicine NY, USA. His interdisciplinary research program integrates immunology, genomics, and computational approaches to develop novel immunotherapies for cancer and autoimmune diseases. With a background spanning physics, theoretical biology, and biophysics, Luciani leads an interdisciplinary team with expertise in immunology, mathematical modeling, statistics, and bioinformatics. His research focuses on T cell responses using single-cell genomic technologies to understand immune responses in viral infections, autoimmunity, and CAR T cell therapies. He has developed landmark bioinformatic methods for combining single-cell transcriptome data with antigen receptor sequences and computational models for haplotype reconstruction. Luciani's work demonstrates a strong emphasis on translating molecular and genomic discoveries into clinical interventions, particularly in predicting side effects and identifying solutions for unmet clinical needs in immunotherapy. His research spans multiple collaborative projects including single-cell multi-omics analysis in coeliac disease with Prof Chris Goodnow's team at the Garvan Institute, and CAR T cell therapy response studies with clinicians at Westmead Hospital and Weill Cornell. His scientific contributions include over 140 peer-reviewed publications and successful acquisition of more than $20 million in research funding from organizations including ARC, NHMRC, JDRF, NIH, and private industry partners. He serves as Principal Investigator of the UNSW Future Institute of Cellular Genomics, which has secured $4.5 million over seven years for single-cell technologies in cellular genomics. As an academic supervisor, Luciani currently mentors 3 PhD students, 2 honours students, and 2 postdoctoral researchers, welcoming applications from students interested in bioinformatics, statistics, data science, immunology, and genomics. His work bridges theoretical approaches with experimental immunology to advance precision medicine and transform current immunotherapies into more precise and accessible solutions.

پروفایل رسمی دانشگاه

Dennis C. Sgroiمشاهده پروفایل

استاد

RWTH Aachen UniversityGermany

Dennis C. Sgroi, MD, is Professor of Pathology at Harvard Medical School and Executive Vice-Chair of Pathology at Massachusetts General Hospital (MGH), where he also serves as Director of Breast Pathology. He leads the Sgroi Laboratory within the Molecular Pathology Unit and the Krantz Family Center for Cancer Research at MGH. Education & Training: MD, University of Connecticut School of Medicine Residency, Massachusetts General Hospital Fellowship, Massachusetts General Hospital Board certified: Anatomic & General Pathology, American Board of Pathology Research Focus: Dr. Sgroi’s laboratory integrates multi-omics technologies to discover and validate molecular biomarkers that predict breast-cancer recurrence and therapeutic response. Core projects include the clinically-adopted Breast Cancer Index (BCI) assay (HOXB13/IL17RB), deciphering HOXB13-mediated tumor-microenvironment remodeling in ER-positive and triple-negative breast cancer, and developing combinatorial therapies targeting HOXB13/ERBB2 co-amplified tumors with BRCA1 loss. Clinical Impact & Guidelines: The BCI biomarker has been prospectively validated in multiple randomized trials (NSABP-B-42, Trans-aTTom) and is now incorporated into NCCN and ASCO treatment guidelines for extended adjuvant endocrine therapy in post-menopausal women with ER-positive breast cancer. Scientific Awards & Honors: While individual awards are not enumerated in the supplied text, the sustained funding of ~ $19 million in annual direct research costs attests to national peer-review recognition. Research Team & Collaborations: The Sgroi Lab includes post-doctoral fellows, graduate researchers, and staff scientists such as Marinko Sremac, PhD. Collaborative networks span Dana-Farber/Harvard Cancer Center Breast Cancer and Cancer Genetics Programs, NRG Oncology, and international genomic consortia.

پروفایل رسمی دانشگاه

Karol Nowicki-Osuchمشاهده پروفایل

پژوهشگر ارشد

German Cancer Research CenterGermany

Dr. Karol Nowicki-Osuch is a Group Leader at the German Cancer Research Center (DKFZ) , leading a research group focused on tumorigenesis and molecular cancer prevention. His work emphasizes understanding early stages of gastrointestinal tumor development using multimodal techniques like single-cell RNA sequencing, organoid models, and spatial transcriptomics. Key research areas include the molecular mechanisms underlying Barrett's esophagus, gastric intestinal metaplasia, and the transition to adenocarcinoma. Collaborations span institutions in Germany, Poland, the UK, and the US. His team investigates how normal epithelial cells lose molecular identity and progress to precancerous states. Notable achievements include demonstrating that esophageal adenocarcinoma originates from gastric tissue and identifying novel mutational signatures using the mutREAD method. Current projects aim to develop early cancer detection strategies and in vivo models of tumor progression. Dr. Nowicki-Osuch supervises PhD students and employs cutting-edge technologies such as spatial transcriptomics and organoid platforms. His lab integrates computational biology with experimental approaches to address gaps in understanding clonal evolution and somatic mutations in gastroesophageal cancers.

پروفایل رسمی دانشگاه

Avraam Tapinosمشاهده پروفایل

پژوهشگر

The University of ManchesterUnited Kingdom

Avraam Tapinos is a Researcher at the University of Manchester's Division of Cancer Sciences (L5), part of the Manchester Cancer Research Centre. His work contributes to UN Sustainable Development Goals related to health and innovation. Research focuses include cancer genomics, metagenomics, and bioinformatics methodologies. Affiliations: Manchester Cancer Research Centre, Digital Futures Research Beacon Key expertise: Cancer genomics, germline analysis, metagenomic binning Recent research explores genomic landscapes of testicular germ cell tumors, breast cancer evolution in diverse populations, and respiratory virome dynamics in asthma. His computational methods advance alignment-free genomic analysis. Publications span high-impact journals like Nature Communications and American Journal of Human Genetics, with interdisciplinary collaborations in oncology, microbiology, and bioinformatics.

پروفایل رسمی دانشگاه

Lukas Edward Dowمشاهده پروفایل

استاد

Cornell UniversityUnited States

Lukas Edward Dow is a Professor of Biochemistry and Biophysics at Weill Cornell Medical College (2025-present) and holds a secondary appointment in Medicine. His research spans genetic and non-genetic resistance mechanisms in KRAS-driven cancers, WNT signaling, and CRISPR-based cancer modeling. Ph.D. and B.Sc. from University of Melbourne Focus on CRC, pancreatic, breast, and prostate cancers Research interests include genetic resistance mechanisms , CRISPR applications , WNT pathway dependencies , and tumor microenvironment dynamics . Key publications reveal trends in mutant-specific therapies , epithelial plasticity , and precision genome editing . Current research projects funded by National Cancer Institute and Department of Defense investigate KRAS allelic imbalance, R-Spondin sensitization, and WNT pathway alterations. External collaborations include scientific advisory roles at Mirimus, Inc. and consulting at Revolution Medicines, Inc. His lab develops genetically engineered mouse models and organoid systems for studying cancer progression, with emphasis on metastasis , drug resistance , and epigenetic adaptations . The work has significant implications for improving cancer therapies through context-dependent targeting .

پروفایل رسمی دانشگاه